BarryRosenbloomMD

PubMed

• 12 citations
  Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
  Barry E Rosenbloom, Maria Domenica Cappellini, Neal J Weinreb, Marta Dragosky, Shoshana Revel-Vilk
  American Journal of Hematology. 2022-10-01
• 4 citations
  Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.
  Grant Bonesteele, J. Jay Gargus, Emily Curtin, Mabel Tang, Barry E. Rosenbloom
  Molecular Genetics and Metabolism Reports. 2020-12-01
• 19 citations
  Gaucher disease and SARS-CoV-2 infection: Emerging management challenges.
  Pramod K. Mistry, Manisha Balwani, Deborah Barbouth, T. Andrew Burrow, Edward I. Ginns
  Molecular Genetics and Metabolism. 2020-07-01

Journal Articles

• Bone disease in patients with Gaucher disease  
  Rosenbloom BE, Weinreb NJ, Expert Rev Endocrin Metab, 1/1/2014
• Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly  
  Weinreb NJ, Rosenbloom BE, Open J Genet, 1/1/2013
• Gaucher disease: a comprehensive review  
  Rosenbloom BE, Weinreb NJ, Crit Rev Oncog, 1/1/2013
• Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism  
  Mistry PK, Taddei T, Vom Dahl S, Rosenbloom BE, Crit Rev Oncog, 1/1/2013
• A multicenter, open-label treatment protocol (HGT GCB 058) of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease: safety and tolerab...  
  Pastores G, Rosenbloom B, Weinreb N, et al, Genet Med, 1/1/2013
• Open-label extension study following late-onset treatment study (LOTS) of alglucosidase alfa  
  van der Ploeg, AT, Rosenbloom BE, et al, Molec Genet Metab, 1/1/2012
• Clinical characteristicws associated with persisting thrombocytopenia in type 1 Gaucher patients treated with imiglucerase for 4 to 5 years  
  Hollak, CEM, Belmatoug N, Cole A, Vom Dahl, S, Deegan P, Goldblatt J, Rosenbloom B van Dussen L, Tylki-Szymanska, Weinreb, N, Zimran, A, Cappellini, MD, Brit J Haematol, 1/1/2012
• The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry  
  Rosenbloom B, Balwani M, Bronstein J, et al, Blood Cells, Mol Dis, 1/1/2011
• Cardiovascular abnormalities in late-onset Pompe disease an response to enzyme replacement therapy  
  Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK, Rosenbloom BE, et al, Genet Med, 1/1/2011
• A preliminary analysis from the ICGG Gaucher registry: short-term clinical outcomes in Gaucher patients affected by the shortage of imiglucerase  
  Weinreb N, Rosenbloom B, Andersson, H, Cole C, Tripuraneni R, Belmatoug N, Mol Genet Metab, 1/1/2011
• A randomized study of Alglucosidase alfa in late onset Pompe disease  
  van der Ploeg AT, Rosenbloom BE, et al, New Engl J Med, 1/1/2010
• Left ventricular thrombus and embolic stroke caused by a functional paraganglioma  
  Buchbinder NA, Yu r, Rosenbloom BE, Sherman CT, Silberman AW, J Clin Hypertension, 1/1/2009
• Multiple myeloma and Gaucher Genes  
  Rosenbloom BE, Weinreb N, Becker P, Genetics in Medicine, 1/1/2009
• Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifectations of type I Gaucher disease: results of a 48-month longitudinal c...  
  Sims, KB, Pastores, GM, Werinreb NJ, Barranger J, Rosenbloom BE, et al, Clin Genet, 1/1/2008
• Prevalence of type 1 Gaucher disease in the United States  
  Weinreb NJ, Andersson HC, Rosenbloom BE, et al, Arch Int Med, 1/11/2007
• The antipoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B-cell chronic lymphoid leukemia  
  Krejci P, Pejchalova K, Rosenbloomc BE, J Leuk Biol, 1/1/2007
• Primary hepatic carcinoid presenting with Cushing's syndrome  
  Shah NA, Rosenbloom B, et al, J Endocrinol Invest, 1/1/2007
• Imiglucerase(cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease  
  Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, et al, Clin Genet, 1/1/2007
• Individualiztion of long-term enzyme replacement therapy for Gaucher disease  
  Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakesh Cheng A, Rosenbloom, BE, et al, Genet Med, 1/1/2005
• Gaucher disease and cancer incidence: a study from the Gaucher registry  
  Rosenbloom, BE, Weinreb, NJ, Zimran, A, Kacena, KA, Charrow, J, Ward, E, Blood, 1/1/2005
• Gaucher disease type I: revised recommendations on evaluations and monitoring for adult patients  
  Weinreb, NJ, Aggio, MC, Andersson, HC, Rosenbloom, BE, Semin Hemat, 1/1/2004
• Enzyme replacement therapy and monitoring for children with type I Gaucherdisease: consensus recommendations  
  Charrow J, Andersson HC, Rosenbloom BE, et al, J. Pediat., 1/1/2004
• Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease  
  Papadakis P, Rosenbloom, BE, Targan S, Gastroenterology, 1/1/2003
• Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy  
  Santoro D, Rosenbloom BE, Cohen AH, Amer J Kid Dis, 1/1/2002
• Effectiveness of enzyme replacement therapy in 1, 028 patients with type I Gaucher disease after 2-5 years of treatment: a report from the Gaucher registry  
  Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A, Amer J Med, 1/1/2002
• Join now to see all

Books/Book Chapters

• Advances in Gaucher disease: Basic and clinical Perspectives 
  Chapter: Gaucher Disease: A Comprehensive Review. 
  Rosebloom, Barry E, Weinreb, Neal JEditors: Grabowski, GA.Future Medicine, London, UK2013
• Online Metabolic and Molecular Basis of Inherited Disease 
  Chapter: Gaucher disease: phenotypic and genetic variation. 
  Grabowski, G, Kolodny, E, Weinreb, N, Rosenbloom B, et al2011
• Hematology, Basic Principles and Practice 
  Chapter: "Hematological problems in patients with cancer and chronic inflammatory disorders" 
  Page 2410 - 2419Weinstein, IM, Rosenbloom, BEChurchill Livingstone, New YorkEdition 3rd,1999
• Hematology: Basic Principles and Practice 
  Chapter: "Hematologic Problems in Patients with Cancer and Chronic Inflammatory Disorders" 
  Page 2144 - 2154Weinstein, I.M., Rosenbloom, B.E.Editors: Furie, B. et. al..Churchill Livingstone, New YorkEdition 2nd,1994
• Altered Glycosylation in Tumor Cells 
  Chapter: The use of myltiple tumor markers to monitor cancer patients. 
  Page 295 - 299Chia, D., Terasaki, P.I., Wiseman, C., Rosenbloom, B.E., Ouwendijk, R., Tokita, K.Alan R. Liss1988
• Ambulatory Care for the House Officer 
  Chapter: "Anemia" 
  Page 172 - 178Rosenbloom, BEEditors: Diamond, NJ, Guze, P.Williams & Wilkens, Baltimore1982
• Join now to see all

Abstracts/Posters

• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Rosenbloom B, et al, World Conference on Lysosomal Storage Disease, 1/1/2015
• Stability is maintained in adult patients with Gaucher disease type 1 switched from velaglucerase to eliglustat: a sub-analysis of the eliglustat ENCORE trial.
  Pleat R, Mankowski R, Angell J, Rosenbloom B, World Congress of Lysosomal Storage Diseases, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Rosenbloom B, et al, ASH, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, SSIEM, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, ASHG, 1/1/2014
• Encore: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replace...
  Cox TM, Drelichman G, Rosenbloom B, et al, Eur Work Grp Gaucher Dis (EWGGD), 1/1/2014
• Validation study of a DS3 severity score index for adult patients with type 1 Gaucher disease (GD1).
  Weinreb NJ, Finegold D, Feingold E, Rosenbloom B, Shankar S, amato D, World Conf Lysomal Stor Dis, 1/1/2014
• ENCORE: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therap...
  Burrows TA, Balwani M, Cox T, Rosenbloom B, et al, Amer Soc Hemat, 1/1/2013
• Encore: a multi-national, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme re...
  Balwani M, Rosenbloom B, et al, Amer Soc Med Genet, 1/1/2013
• Encore: a multi-national, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme re...
  Cox T, Dreclichman G, Cravo R, Balwani M, Rosenbloom B, et al, ICIEM, 1/1/2013
• A Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease: safety and tolerab...
  Pastores GM, Rosenbloom B, Weinreb N, et al, COLATEL 2013 Meeting, Buenos Aires, Argentina, 1/1/2013
• Multicentre open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy (ERT) for type 1 Gaucher (GD1): safety and tolerability.
  Pastores G, Rosenbloom B, Grabowski G, Weinreb, N, Mardach R, Ibrahim J, Mistry P, Internat Workshop on Lysosomal Strorage Dis, London, UK, 1/2/2012
• Ibrahim J, Pastores GN, Rosenbloom B, et al, ASHG, 1/1/2012
• Safety of velaglucerase alfa in relation to positive baseline anti-imiglucerase antibody status in type 1 Gaucher disease patients from the treatment protocol HGT-GCB-...
  Pastores GM, Rosenbloom B, Goker-Alpan O, et al, ASHG, 1/1/2012
• Safety if velaglucerase alfa in type 1 Gaucher disease patients with anti-imiglucerase antibodies.
  Goker-Alpan O, Pastores G, Rosenbloom B, et al, ASHG, 1/1/2012
• Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease (GD-1): safety and tolerabili...
  Pastores G, Rosenbloom B, Grabowski G, et al, SSIEM, Geneva Switzerland, 1/30/2011
• Multicenter, open-label study of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease (GD1): safety evaluation of the first three infusions fr...
  Pastores G, Rosenbloom B, Weinreb N, et al, Europ Human Genet Conference, Amsterdam, 1/28/2011
• Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement (ERT) in type 1 Gaucher disease: safety and tolerability.
  Pastores G, Rosenbloom B, Weinreb N, et al, Europ Human Genet Conference, Amsterdam, 1/28/2011
• Multicenter, open-label study of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease: 3-month results from the HGT-GCB-058 treatment protocol.
  Pastores GM, Rosenbloom B, Grabowski, G, et al, Amer Coll Med Genet, 1/18/2011
• Thrombocytopenia in the absence of splenomegaly in patients with type 1 Gaucher disease: a preliminary analysis from the ICGG Gaucher Registry.
  Rosenbloom BE, Kulke S, Taylor J, Weinreb NJ, Amer Soc Hematol, 1/11/2011
• Report on the safety of velaglucerase alfa enzyme replacement therapy in patients with type 1 Gaucher disease and the transition from clinic to home infusions during t...
  Pastores GM, Rosenbloom B, Weinreb N, et al, Amer Soc Hematol, 1/10/2011
• A preliminary analysis from the ICGG Gaucher registry: short-term clinical outcomes in Gaucher patients affected by the shortage of imiglucerase.
  Weinreb N, Rosenbloom B, Andersson H, Belmatoug N, World Conference on LSD's, 1/1/2011
• Multicenter, open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy (ERT) in type 1 Gaucher disease (GD-1): safety and tolerabili...
  Pastores G, Rosenbloom B, Grabowski G, et al, Eur Soc Hum Genet; SE Reg Genet Grp, 1/1/2011
• Determinants of persisting thrombocytopenia in patients with type 1 Gaucher disease treated with alglucerase/imiglucerase for 4-5 years.
  Cappellini MD, Rosenbloom B, et al, Eur Soc Hem, 1/1/2011
• An analysis from the ICGG Gaucher Registry: a report of Gaucher patients affected by reduced dose of imiglucerase.
  Weinreb N, Rosenbloom B, Andersson H, et al, World Confererence on LSD's, 1/1/2011
• Join now to see all

Other

• Ask the Expert. 
  Rosenbloom, BE, Horizons, A Newsletter for the Gaucher Community
  1/1/2008
• Consensus startement by the ICGG (International Cooperative Gaucher Group) U.S. regional coordinators on individualization of enzyme replacement therapy(ERT) for type ... 
  Andersson HC, Charrow J, Kaplan P, Kolodny EH, Mistry PK, Pastores GM, Rosenbloom BE, et al.
• "Meet the Experts: Gaucher diseasae (Diagnosis, Gaucher and Parkinsonism, Gaucher and myeloma, Cerdelga, )" (Teaching Video) 
  Rosenbloom B, Weinreb, N